The global anti-obesity drugs market is gaining significant momentum with the introduction of new drugs by Novo Nordisk and Eli Lilly in the US, UK, and Europe.
Novo Nordisk has launched Semaglutide Injection, a GLP-1 receptor agonist, under two brands, Wegovy and Ozempic.
Eli Lilly, on the other hand, introduced Tirzepatide Injection, a dual GIP/GLP-1 receptor agonist, with two brands named Zepbound and Mounjaro.
Projections indicate that the global market with these new anti-obesity drugs, including Zepbound, Mounjaro, Wegovy, and Ozempic, is anticipated to reach $100 billion by the end of the decade.
Presently, 38% of the world population, totaling 2.6 billion people, is overweight or obese. If current trends continues , it is expected that this number will surpass 4 billion, constituting 51% of the global population in the next 12 years.
Obesity is linked to increased morbidity and mortality, elevating the risk of developing conditions such as diabetes, hypertension, hyperlipidemia, and other cardiovascular diseases.
Recognising the substantial market potential, both Novo Nordisk and Eli Lilly plans to launch these patented anti-obesity drugs in India.
Success in India is anticipated to be driven by several key factors, including
– First-mover Advantage
– Marketing Strategy
– Doctor Coverage
– Patient Activation
– Pricing Strategy
Additionally, the response of the Indian population to the efficacy and safety profiles of these drugs will also be a crucial factor
Expectations are high for notable advancements in the coming years.
433, Shantivan, Near Tarapore Gardens, New Link Road Extension, Andheri West,
Mumbai 400053, India.
